SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid's stock is trending downwards, with the community expressing concerns about the company's financial future and comparing it unfavorably to competitors like Tesla and Rivian. Recent news of price cuts on existing models and a cheaper Gravity SUV trim has some worried about potential margin impacts, while others question the company's leadership and strategy. Despite some positive sentiment regarding Lucid's technology, overall sentiment appears quite negative.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

Fly-E Group is trending due to high volatility and speculation of a potential short squeeze, evidenced by a massive increase in trading volume. The community is actively discussing dark pool short interest and debating whether the stock can repeat the dramatic moves of similar plays, while others warn of the risks associated with pump-and-dump schemes and the company's fundamentals.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is trending due to upcoming data presentations at the ASH conference, particularly for its IRAK1/4 inhibitor R289, with potential implications for the lucrative MDS market. Community discussions revolve around buyout potential, low P/E ratio, and speculation about short positions ahead of these events. Bullish sentiment is fueled by institutional ownership and revenue growth, while some traders eye options and potential short squeezes.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending after crushing earnings expectations, with revenue and EPS significantly exceeding estimates, leading to bullish sentiment and analysts raising price targets. The community is discussing the stock's potential for continued growth in the AI space and comparing it to competitors like Oracle. Some traders caution about valuation and potential pullbacks, while others highlight the stock's strength and potential for further gains.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as investors assess the impact of AI leadership changes and a potential product supercycle in 2025. Community discussions revolve around Apple's AI strategy amid leadership transitions, while some analysts highlight the stock's potential breakout toward the $300 level. Broader market sentiment reflects a mix of optimism and caution, with some concerned about consumer health and the overall economic outlook.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending due to community speculation around a potential Nasdaq relisting and excitement surrounding its pivot towards becoming an AI-driven fintech platform, CapForce. Investors are closely watching for news on the CapForce launch and further updates from AEI Capital, the company's major shareholder, with some expressing hope for a significant upward move. The community is actively discussing potential valuation and the impact of recent filings on the company's compliance status.

AI TRAINING DATA 🤝 PREDICTION MARKETS  On REPPO.AI, user A publishes AI collabs - Vibe coded apps, GenAI videos/images, interaction with robots etc. & user B predicts quality by voting in weekly epochs. Both split emissions 50-50 while high quality AI training data is created.

REPPO

REPPO is experiencing a surge in interest, with community members highlighting its recent gains. Discussions suggest some investors are drawing attention to REPPO as an alternative investment. The increased visibility is prompting broader awareness of the token within the crypto space.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is trending as investors weigh its role in the current economic landscape, with discussions focusing on inflation hedges as gold gains traction. Community members are actively debating executive orders, political commentary, and potential recession indicators, alongside the fund's dividend yield and expense ratio. Economic uncertainty and geopolitical tensions are also driving interest in this inflation-protected security.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Panda ($PANDU) is gaining traction, with community members highlighting its strong community, consistent development, and potential utility within the Solana ecosystem. Discussions revolve around its low market cap relative to potential upside, branding, and upcoming announcements, leading to increased attention and trending status.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave ($CRWV) is trending amid concerns about AI infrastructure competition and overall sector valuations, particularly with growing discussion around hyperscalers developing their own chips. The community is debating the company's debt levels and potential for future offerings, alongside contrasting views on its long-term viability and comparisons to competitors. Despite bearish sentiment from some, others highlight strong revenue backlog, support from NVDA, and recent purchases from Cathie Wood as reasons for optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marker Therapeutics (NASDAQ:MRKR)  Shares Down 2.7%

Marker Therapeutics, Inc. (NASDAQ:MRKR - Get Free Report)'s share price traded down 2.7% on Friday . The company traded as low as $4.66 and last traded at $4.75. 31,276 shares traded hands during...

Marker Therapeutics Advances in Immuno-Oncology

Marker Therapeutics (MRKR) has released an update. Marker Therapeutics has announced significant strides in its immuno-oncology programs, including...

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

Marker Therapeutics Ends Stock Sale Deal with LPC

An announcement from Marker Therapeutics Inc (MRKR) is now available. Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincol...

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for  Neldaleucel  as Nonproprietary Name for MT-601

HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...

Marker Therapeutics (NASDAQ:MRKR) Shares Up 0.4%

Marker Therapeutics, Inc. (NASDAQ:MRKR  Get Free Report)s stock price shot up 0.4% on Tuesday . The company traded as high as $5.00 and last traded at $4.96. 28,057 shares were traded...

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product...

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Marker Therapeutics Inc

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

Current Price	$1.18
Prev Close	$1.24
Open	$1.26
Dividend Yield	0.00%
50-Day Moving Average	$0.9957
Beta	1.18
Avg. Volume	278,495.26
PE Ratio	-0.96

52-Week High	$5.95
52-Week Low	$0.8099
Market Capitalization	$20.67M
EPS (Annual)	-$1.20
Price to Book	1.07
Revenue Per Employee	$1.32M
Enterprise Value/EBITDA	N/A

MRKR
Marker Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MRKR News

MRKRMarker Therapeutics Inc